Enoximone - CAS 77671-31-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Phosphodiesterase (PDE)
Enoximone is a selective phosphodiesterase III (PDE3) inhibitor. It can be used for the treatment of heart failure.
Publictions citing BOC Sciences Products
  • >> More
light yellow solid
1,3-Dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one; Fenoximone; MDL 17043; Perfan; Perfane; RMI 17043;
DMSO: soluble28 mg/mL
-20℃ Freezer
Heart failure
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Canonical SMILES:
Current Developer:
Originator sanofi-aventis
1.A Bayesian network meta-analysis on the effect of inodilatory agents on mortality.
Greco T1, Calabrò MG1, Covello RD1, Greco M1, Pasin L1, Morelli A2, Landoni G3, Zangrillo A1. Br J Anaesth. 2015 May;114(5):746-56. doi: 10.1093/bja/aeu446. Epub 2015 Feb 4.
BACKGROUND: Inodilators are commonly used in critically ill patients, but their effect on survival has not been properly studied to date. The objective of this work was to conduct a network meta-analysis on the effects of inodilators on survival in adult cardiac surgery patients, and to compare and rank drugs that have not been adequately compared in head-to-head trials.
2.Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock.
den Uil CA1, Lagrand WK2, van der Ent M3, Nieman K1, Struijs A1, Jewbali LS1, Constantinescu AA1, Spronk PE4, Simoons ML1. PLoS One. 2014 Aug 1;9(8):e103978. doi: 10.1371/journal.pone.0103978. eCollection 2014.
AIM: To investigate the effects of inotropic agents on parameters of tissue perfusion in patients with cardiogenic shock.
3.Emergency treatment of status asthmaticus with enoximone.
Beute J1. Br J Anaesth. 2014 Jun;112(6):1105-8. doi: 10.1093/bja/aeu048. Epub 2014 Mar 17.
This report describes the treatment of eight patients with status asthmaticus, six of whom were already maximally treated. They were consequently treated with enoximone, a selective phosphodiesterase III inhibitor, in their refractory phase. Bronchodilatation in these patients was immediate. No side-effects were observed. Enoximone appears to be a valuable addition to the treatment of status asthmaticus. I.V. administration bypasses inhalation incapability in severe asthma. It is likely to reduce or altogether prevent the need for resorting to secondary or tertiary high-tech therapy such as mechanical ventilation or anaesthetics, thus avoiding complications, as well as for transfers to specialized intensive care units. Not only do these aspects enable substantial cost savings, but they also may spare the patient a lot of anguish and a prolonged recovery.
4.Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
Erb J1, Beutlhauser T2, Feldheiser A2, Schuster B2, Treskatsch S2, Grubitzsch H3, Spies C4. J Int Med Res. 2014 Jun;42(3):750-64. doi: 10.1177/0300060513516293. Epub 2014 Apr 29.
OBJECTIVES: Levosimendan is an inotropic drug with organ-protective properties due to its activation of mitochondrial K(ATP) channels. This prospective, randomized, double-blind, placebo-controlled study investigated whether administration of levosimendan prior to cardiopulmonary bypass could reduce organ dysfunction and influence subsequent secondary endpoints.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products

CAS 225100-12-9 PDE IV-IN-1

(CAS: 225100-12-9)

An inhibitor of phosphodiesterase IV with potential for the treatment of asthma, COPD or other inflammatory diseases.

CP 461
(CAS: 227619-96-7)

CP 461, belonging to a class of novel proapoptotic drugs with antineoplastic effect, specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1...

CAS 1904611-63-7 PDE1-IN-2

(CAS: 1904611-63-7)

PDE1-IN-2 is an inhibitor of PDE1 that has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.

CAS 58579-51-4 Anagrelide Hydrochloride

Anagrelide Hydrochloride
(CAS: 58579-51-4)

Anagrelide is a drug used for the treatment of essential thrombocytosis,or overproduction of blood platelets. It also has been used in the treatment of chronic ...

(CAS: 1239278-59-1)

This active molecular is a Type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor originated by Chiesi Farmaceutici with IC50 value of 0.026 ± 0.006 nM. CH...

CAS 141184-34-1 Filaminast

(CAS: 141184-34-1)

Filaminast is a Type 4 cyclic nucleotide phosphodiesterase inhibitor. It is an analog of rolipram which served as a prototype molecule for several development e...

CAS 61-25-6 Papaverine hydrochloride

Papaverine hydrochloride
(CAS: 61-25-6)

Papaverine hydrochloride, an opium alkaloid antispasmodic, is a selective phosphodiesterase inhibitor used primarily in the treatment of visceral spasm, vasospa...

CAS 73963-72-1 Cilostazol

(CAS: 73963-72-1)

Cilostazol is a potent cyclic nucleotide phosphodiesterase type 3 (PDE3) inhibitor with IC50 of 0.2 μM and inhibitor of adenosine uptake.

CAS 13460-98-5 Theodrenaline

(CAS: 13460-98-5)

Theodrenaline, also known as noradrenalinoethyltheophylline, is a cardiac stimulant with anti-hypotensive property together with cafedrine.

CAS 81840-15-5 Vesnarinone

(CAS: 81840-15-5)

Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...

CAS 224789-15-5 Vardenafil dihydrochloride

Vardenafil dihydrochloride
(CAS: 224789-15-5)

Vardenafil, also called as Levitra and Nuviva, is a phosphodiesterase inhibitor that is selective for PDE5 and PDE1 (IC50 = 0.7 and 180 nM, respectively).

BRL 50481
(CAS: 433695-36-4)

BRL 50481 is a potent, selective substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (Ki = 180 nM).

CAS 439083-90-6 Bay 60-7550

Bay 60-7550
(CAS: 439083-90-6)

Bay 60-7550 is a potent PDE2 inhibitor. It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B...

CAS 1013750-77-0 ML-030

(CAS: 1013750-77-0)

ML-030, a triazolothiadiazine, is a potent PDE4 inhibitor in a cell-based cyclic nucleotide-gated cation channel biosensor assay (EC50 = 18.7 nM), with IC50 of ...

CAS 1238697-26-1 TAK-063

(CAS: 1238697-26-1)

TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...

PDE10-IN-1 is a potent PDE10-IN-1 inhibi
(CAS: 1516896-09-5)

PDE10-IN-1 is a potent PDE10-IN-1 inhibitor which can be used to treat CNS disorders and metabolic disorders.

CAS 74150-27-9 Pimobendan

(CAS: 74150-27-9)

Pimobendan is both a calcium sensitizer and a selective inhibitor of phosphodiesterase III (PDE3) with positive inotropic and vasodilator effects.

CAS 192819-27-5 CDC801

(CAS: 192819-27-5)

A potent, orally active and dual inhibitor of phosphodiesterase 4 (PDE4) (IC50= 1.1 μM) and tumor necrosis factor-α (TNF-α) (IC50= 2.5 μM).

(CAS: 1035572-38-3)

LEO29102 is a potent, selective, and soft-drug phosphodiesterase 4 (PDE4) inhibitor. It shows properties suitable for patient-friendly formulations giving effic...

CAS 1440898-61-2 Deltarasin

(CAS: 1440898-61-2)

Deltarasin inhibits the interaction of RAS with PDEδ with KD of 41 nM. Inhibition of PDEδ-KRAS interaction by Deltarasin suppresses proliferation of human pancr...

Chemical Structure

CAS 77671-31-9 Enoximone

Quick Inquiry

Verification code

Featured Items